Keywords
Antitubercular Agents
Drug-Related Side Effects and Adverse Reactions
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze occurrences of adverse reactions related to the treatment of tuberculosis and their association with clinical variables and outcome in a city in the interior of the Amazon. Methods: This is a cross-sectional, descriptive and documental study, in which 90 medical records of patients with tuberculosis treated at a health unit between the years 2015 and 2022 were analyzed. sociodemographic data, clinical characteristics and outcome of patients through a form prepared by the researchers. Results: Most patients were male, aged between 45 and 59 years, single, brown and from Santarém. There was a prevalence of pulmonary tuberculosis. Most patients (90%) had adverse reactions to treatment. Minor adverse effects prevailed (78.3%) with emphasis on gastrointestinal ones. Most were cured of the disease (60%); 15.6% evolved to death; 13.3% were still undergoing treatment; 7.8% did not complete the treatment due to abandonment. Conclusion: It is concluded that the occurrence of adverse reactions, for the most part, were minor, such as epigastric pain, nausea, vomiting, joint pain, headache and mild itching, without major repercussions for the patient and treatment, being managed only with guidelines general and symptomatic.
References
ARBEX MA, et al. Drogas antituberculose: interações medicamentosas, efeitos adversos e utilização em situações especiais. Jornal Brasileiro de Pneumologia, 2010; 36 (5): 626-656.
BALLESTERO JGA, et al. Management of multidrug-resistant tuberculosis: main recommendations of the brazilian guidelines. Jornal Brasileiro de Pneumologia, Sociedade Brasileira de Pneumologia e Tisiologia, 2020; 46(2): 201-290.
BATES MN. Risk of Tuberculosis From Exposure to Tobacco Smoke. Archives Of Internal Medicine, 2007; 167(4): 335.
BRASIL. Ministério Da Saúde. Secretaria de Vigilância em saúde. Boletim epidemiológico de Tuberculose, 2022. Disponível em: https://www.gov.br/saude/pt-br/centrais-de conteudo/publicacoes/boletins/epidemiologicos/especiais/2022/boletim-epidemiologico-de-tuberculose-numero-especial-marco-2022.pdf. Acessado em: 10 de dezembro de 2022.
BRASIL. Ministério Da Saúde. Secretaria de vigilância em saúde. Departamento de vigilância das doenças transmissíveis. Manual de Recomendações para o controle da tuberculose no brasil. 2019. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/tuberculose/manual-de-recomendacoes-e-controle-da-ttuberculose-no-brasil-2a-ed.pdf/view. Acessado em: 10 de dezembro de 2022.
BRASIL. MINISTÉRIO DA SAÚDE. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Brasil Livre da Tuberculose: Plano Nacional pelo Fim da Tuberculose como Problema de Saúde Pública –estratégias para 2021-2025. Brasília, DF: Ministério da Saúde, 2021. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/brasil_livre_tuberculose_plano_nacional.pdf. Acessado em: 10 de dezembro de 2022.
CONDE MB, et al. III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia. Jornal Brasileiro de Pneumologia, 2009;35(10): 1018-1048.
FRANKS AL, et al. Isoniazid Hepatitis among Pregnant and Postpartum Hispanic Patients. Association Of Schools Of Public Health: Public Health Reports, 1989: 151-155.
GIRLING DJ. Adverse reactions to rifampicin in antituberculosis regimens. Journal Of Antimicrobial Chemotherapy, 1977; 3(2): 115-132.
GONÇALVES LS, et al. Efeitos adversos no tratamento da tuberculose. Enferm. Foco, 2020; 11(3): 178-186.
GUIDONI LM, et al. Catastrophic costs and social sequels due to tuberculosis diagnosis and treatment in Brazil*. Epidemiologia e Servicos de Saude, 2021; 30(2).
JEON CY e MURRAY MB. Diabetes Mellitus Increases the Risk of Active Tuberculosis: a systematic review of 13 observational studies. Plos Medicine, 2008; 5(7): 152.
LIMA MFS e MELO HRL. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cadernos de Saúde Pública, 2012; 28(4): 698-708.
LIN HH, et al. Tobacco Smoke, Indoor Air Pollution and Tuberculosis: a systematic review and meta-analysis. Plos Medicine, 2007; 4(1): 20.
MACIEL ELN, et al. Efeitos adversos causados pelo novo esquema de tratamento da tuberculose preconizado pelo Ministério da Saúde do Brasil. Jornal Brasileiro de Pneumologia, 2010; 36(2): 232-238.
OLIVEIRA HB e MOREIRA FDC. Abandono de tratamento e recidiva da tuberculose: aspectos de episódios prévios, campinas, sp, brasil, 1993-1994. Revista de Saúde Pública, 2000; 34(5): 437-443.
OROFINO RL, et al. Preditores dos desfechos do tratamento da tuberculose. Jornal Brasileiro de Pneumologia, 2012; 38 (1): 88-97.
PEREIRA AA, et al. Gestão e gerenciamento dos níveis hierárquicos do programa nacional de controle da tuberculose. IJHE 2016, 2016; 1(1): 68-71.
QUINTERO MCF, et al.Acesso ao diagnóstico da tuberculose em município brasileiro de médio porte. Rev. salud pública, 2018; 20(1): 103-109.
RESENDE LSO e SANTOS-NETO ET. Risk factors associated with adverse reactions to antituberculosis drugs. Jornal Brasileiro de Pneumologia, 2015; 41(1): 77-89.
SALLES CL, et al. Defaulting from anti-tuberculosis treatment in a teaching hospital in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis., 2004; 8(3): 318-22.
SANCHÍS AM, et al. Primary Prevention and Treatment of Latent Tuberculosis Infection With Isoniazid: efficacy of a control program, 1997-2002. Archivos de Bronconeumología, 2005; 41(1): 27-33.
SANTOS NSGM, et al. Tuberculose e análise espacial: revisão da literatura. Cienc Enferm, 2014; 20(2): 117-129.
SILVA DR, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. Jornal Brasileiro de Pneumologia, 2018; 44(2): 145-152.
SOARES LEITE M, et al. Tuberculose multirresistente: revisão de literatura. Brazilian Journal of Surgery and Clinical Research, 2020; 31(3): 102-107.
SOCIEDADE BRASILEIRA DE PNEUMOLOGIA E TISIOLOGIA. I Consenso Brasileiro de Tuberculose. J Pneumol, 1997; 23(6): 281-342.
VALENZUELA-JIMÉNEZ H, et al. Association of tuberculosis with multimorbidity and social networks. Jornal Brasileiro de Pneumologia, 2017; 43(1): 51-53.
VIEIRA DEO e GOMES M. Efeitos adversos no tratamento da tuberculose: experiência em serviço ambulatorial de um hospital-escola na cidade de São Paulo. J Bras Pneumol, 2008; 34(12):1049-1055.
WHO, WORLD HEALTH ORGANIZATION. Treatment guidelines for drugresistant tuberculosis. WHO – Genebra, 2016. Disponível em: https://www.who.int/publications/i/item/9789241549639. Acessado em: 10 de dezembro de 2022.
WORLD HEALTH ORGANIZATION (WHO). Global tuberculosis report 2021. Geneva: WHO, 2021. Disponível em: https://www.who.int/publications/i/item/9789240037021. Acessado em: 3 de setembro de 2022.
YEE D, et al. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. American Journal Of Respiratory And Critical Care Medicine, 2003; 167(11): 1472-1477.